Clinical Trials

Clinical Trials are essential in the development of new cancer treatments.

In a very small number of patients with a strong family history of pancreatic cancer (two or more close relatives affected), screening using endoscopic ultrasound (EUS) surveillance may be considered. The true value of screening is unknown and is performed as part of research studies. Research has shown that early detection and treatment on pancreatic cancer greatly improves survival rates.

A screening trial at Austin Health is currently underway. This trial combines the work of the departments of Surgery, Gastroenterology, Genetics and the Olivia Newton John Cancer Centre at Austin Health in collaboration with Sydney’s St Vincent’s Hospital and the Garvan Institute of Medical Research. The aim of the study is to identify and screen high-risk individuals using EUS, a diagnostic test to detect small changes to the pancreas.

The Australian Government, National Health and Medical Research Council has created some informative videos about the importance of clinical trials, you can find more information through their website.

The Forgotten Cancers Project

The Forgotten Cancers Project aims to engage with 15,000 Australians who has been diagnosed as an adult, with one of the Project’s less common cancers.

Participants are asked to complete 4 questionnaires and provide a saliva sample for DNA analysis. A saliva collection kit will be mailed to all participants.

Currently the Forgotten Cancers Project is running studies for both pancreatic and liver cancer.

To register for the Pancreas Study click here

To register for the Liver Study click here

For more information contact Pancare by emailing or call us on 1300 881 698

IMPaCT Trial

Individualised Molecular Pancreatic Cancer Therapy (IMPaCT) is a new Australian clinical trial looking at individualising the treatment of patients with metastatic pancreatic cancer.

What is IMPaCT? 

IMPaCT is a randomized phase II clinical trial, assessing standard chemotherapy treatment called Gemcitabine versus personalised treatment based on specific tumor characteristics in patients with recurrent or metastatic pancreatic cancer.

Why is the APGI doing the IMPaCT trial?

Less than 5% of patients with metastatic pancreatic cancer survive more than 5 years and sadly there have been no major improvements in outcomes over the last 20 years. Previous clinical trials in unselected patient populations have shown only modest improvements in survival when using the current standard chemotherapy, Gemcitabine. By selecting patients based on their unique genetic make-up and matching this information to targeted therapies, we hope that the response to these targeted therapies will be much higher, and subsequently improve overall survival.